biotech / news / / The Gateway Pundit
UK researchers are rushing to develop a new Ebola vaccine based on the exact same viral vector platform used in the Oxford/AstraZeneca COVID-19 jab.
The Oxford Vaccine Group is fast-tracking a Bundibugyo Ebolavirus vaccine using the ChAdOx1 platform.
KEY POINTS
- No approved vaccines currently exist for the Bundibugyo strain, unlike the Zaire strain of Ebola.
- Human clinical trials for ChAdOx1 BDBV could begin in two to three months if animal tests succeed.
- The ChAdOx1 platform's flexibility enables rapid adaptation to target emerging pathogens like new Ebola strains.
- Vaccines from the same Oxford team were selected by WHO for outbreak trials in Uganda and beyond.
COMPANIES
Summarized by Newsio from The Gateway Pundit. How we summarize →